Abstract: Described is an intra-mammary teat sealant and a corresponding method of forming a physical barrier in the teat canal of a non-human animal for prophylactic treatment of mammary disorders during the animal's dry period. The method includes the step of infusing a bismuth-free teat seal formulation into the teat canal of the animal. The method also prevents the formation of black spot defect in dairy products, especially cheddar cheese, made from the milk of animals so treated.

Abstract: A method of enhancing soil water infiltration (SWI) and/or reducing soil water repellency (SWR) comprising: treating an area of groundcover with a composition A comprising A1) a block polymer (P) comprising at least one polyethyleneoxide moiety and at least one polypropyleneoxide moiety, and A2) an alcohol alkoxylate (E), wherein the SWI of the area of groundcover is enhanced and/or the SWR of the area of groundcover is reduced after treatment with the composition A.

Abstract: A pharmaceutical composition for administering directly to the pulmonary tract of a subject includes a salt of triiodothyronine and a pharmaceutically acceptable buffer, adjusted to pH of 5.5-8.5. The composition can be administered prophylactically or therapeutically to a subject to treat lung inflammation or pulmonary edema.

Abstract: The invention provides a solid composition of the peripheral mu opioid antagonist axelopran and a combination dosage form of the mu opioid antagonist axelopran sulfate in an immediate release form and an opioid analgesic agent which may be in an extended release, sustained release, modified release, or controlled release form and methods of preparing such a combination dosage form.

Abstract: A combination comprising a dithiocarbamate fungicide, a succinate dehydrogenase fungicide and at least one of ergosterol biosynthesis inhibitor fungicide or a quinone outside inhibitor fungicide.

Abstract: Disclosed are compounds of Formula 1, including all stereoisomers, N-oxides, and salts thereof, wherein Q, Z, R2, R3 and m are as defined in the disclosure. Also disclosed are compositions containing the compounds of Formula 1 and methods for controlling undesired vegetation comprising contacting the undesired vegetation or its environment with an effective amount of a compound or a composition of the invention.

Abstract: A waterless foamable pharmaceutical composition suitable for external administration is disclosed. The composition includes a foamable carrier least one liquefied or compressed gas propellant. The foamable carrier includes at least one liquid oil; at least one silicone and at least one least one stabilizing agent; wherein the stabilizing agent selected from the group consisting of about 0.01% to about 25% by weight of at least one surface-active agent alone or on combination with a foam adjuvant; and about 0% to about 5% by weight of at least one polymeric agent alone or on combination with a foam adjuvant; and mixtures thereof. Pharmaceutical compositions comprising active agents, methods for their preparation, propellants suitable for use with the carriers and uses thereof are further described.

Abstract: The present disclosure is drawn to pharmaceutical compositions and oral dosage capsules containing testosterone undecanoate, as well as related methods. The capsule includes a capsule shell and a capsule fill. The capsule fill can include a solubilizer and about 14 wt % to about 35 wt % testosterone undecanoate based on the total capsule fill. The oral dosage capsule is such that when a single oral administration to a male subject of one or more capsules with a total testosterone undecanoate daily dose of about 350 mg to about 650 mg it provides a ratio of serum testosterone Cmax to serum testosterone Cave of about 2.7 or less. In yet another embodiment, a method for providing a serum concentration of testosterone within a target serum testosterone concentration Cave range for a male subject is provided.

Abstract: The invention relates to herbicidal active compound combinations comprising, carbamoyltriazolinones, and herbicidally active compounds, which combinations are suitable for controlling weeds.

Abstract: The invention relates to the use of compositions which contain A) one or more copolymers, said copolymers containing one or more structural units resulting from a) 19.9 to 75.9 wt.-% of glycerin, b) 0.1 to 30 wt.-% of at least one dicarboxylic acid, and c) 24 to 80 wt.-% of at least one monocarboxylic acid according to formula (I): R1—COOH, wherein R1 is (C5-C29) alkyl; (C7-C29) alkenyl; phenyl or naphthyl, and B) water for reducing drift during the application of a spray emulsion that contains one or more pesticides.

Abstract: The present invention relates to the use of compound (A) according to formula (I) having the chemical name: 3-chloro-5-(trifluoromethyl)pyridine-2-carboxylic acid) for inducing positive growth responses in plants, a composition comprising compound (A) and a new method of plant treatment wherein is compound (A) applied to a plant, a plant part, plant propagation material or the habitat the plant is growing in to induce positive growth responses.

Abstract: The present invention provides a herbicidal combination comprising Saflufencacil in combination at least two herbicides. The first herbicide may be selected from a triazine herbicide, triazinone herbicide, triazole herbicide, triazolone herbicide, or triazolopyrimidine herbicide, and the second herbicide may be at least one dinitroaniline herbicide.

Abstract: A composition comprising microcapsules functionalized with polymerizable functional groups on the surface of said microcapsules wherein the functional groups form covalent bonds with monomers in the continuous phase to enhance the mechanical properties of the composition.

Abstract: Disclosed is a pharmaceutical composition in dry powder form for intranasal administration, having an anti-anaphylactic adrenergic receptor agonist in the form of dry powder for intranasal administration, the composition having solid particles of the active agent in combination with at least one functional additive, and solid particles of an inert carrier.

Abstract: Accordingly, the present invention provides a pharmaceutical oil-in-water nano-emulsion, with a pharmaceutically active substance. The selected pharmaceutically active substance is encased in fatty acid (e.g., monounsaturated fatty acid, cold pressed oil, and/or esterified fatty acid) droplets with the droplets having an average particle size in the range of 10 to 200 nm. The nano-emulsion is also provided with a non-ionic surfactant system, which is a mixture of polyethers, macrogolglycerides and polysaccharides, along with pharmaceutically acceptable adjuvants. The present invention also provides a process for the preparation of pharmaceutical oil-in-water nano-emulsion.

Abstract: Provided is an antibacterial and antifungal composition, including: (A) at least one kind of 1,2-alkanediol having a linear alkyl group containing 6 to 8 carbon atoms; (B) at least one kind of monoalkyl glyceryl ether having a linear alkyl group containing 6 to 8 carbon atoms, a branched alkyl group containing 6 to 8 carbon atoms, or a cycloalkyl group containing 6 to 8 carbon atoms; and (C) at least one kind of aromatic alcohol represented by the following general formula (1): wherein n represents a natural number of from 1 to 4.

Abstract: Aerosol formulations comprising glycopyrronium bromide in combination with formoterol are useful for the prevention or treatment of chronic obstructive pulmonary disease. The formulation further comprises a HFA propellant, a co-solvent, and an amount of inorganic acid sufficient to stabilize both the glycopyrronium bromide and the formoterol components. Optionally the formulation may further comprise beclometasone dipropionate.

Abstract: A degradable and absorbable hemostatic fiber material, a preparation method therefor, and a hemostatic fiber article thereof. The carboxylation degree of the hemostatic fiber material is 10-25%, and the polymerization degree of the hemostatic fiber material is 10-250. The hemostatic fiber material comprises fiber filaments, the linear density of the fiber filament being 0.8-4.5 dtex, and the dry strength of the fiber filament being 10-150 cN/tex. The degradable and absorbable hemostatic fiber material has a higher carboxylation degree and a lower polymerization degree, while the strength and completeness of the fiber filament can be well maintained, such that the hemostatic effect is better and the hemostasis is faster. Further, the hemostatic fiber material can be degraded and absorbed, and thus is safer.

Abstract: An antimicrobial coating is disclosed that provides fast transport rates of biocides for better effectiveness to deactivate SARS-CoV-2 and other viruses or bacteria on common surfaces. Some variations provide an antimicrobial structure comprising: a solid structural phase comprising a solid structural material; a continuous transport phase that is interspersed within the solid structural phase, wherein the continuous transport phase comprises a solid transport material; and an antimicrobial agent contained within the continuous transport phase, wherein the solid structural phase and the continuous transport phase are separated by an average phase-separation length from about 100 nanometers to about 500 microns. The antimicrobial structure is capable of destroying at least 99.99 wt % of bacteria and/or viruses in 10 minutes of contact. Many options are disclosed for suitable materials to form the solid structural phase, the continuous transport phase, and the antimicrobial agent.

Abstract: The present disclosure is drawn to pharmaceutical compositions and oral dosage capsules containing testosterone undecanoate, as well as related methods. The capsule includes a capsule shell and a capsule fill. The capsule fill can include a solubilizer and about 14 wt % to about 35 wt % testosterone undecanoate based on the total capsule fill. The oral dosage capsule is such that when a single oral administration to a male subject of one or more capsules with a total testosterone undecanoate daily dose of about 350 mg to about 650 mg it provides a ratio of serum testosterone Cmax to serum testosterone Cave of about 2.7 or less. In yet another embodiment, a method for providing a serum concentration of testosterone within a target serum testosterone concentration Cave range for a male subject is provided.